Neurim Pharmaceuticals, Ltd.
Neurim Pharmaceuticals is dedicated to discovering and developing innovative medicines for CNS-related disorders, with a focus on improving patients' lives through constant innovation. Established in 1991, the company has a global presence, with products in over 40 countries, and collaborates with public and private healthcare organizations. Their mission emphasizes pioneering research, strategic partnerships, and addressing unmet needs in CNS disease management.
Industries
Nr. of Employees
small (1-50)
Neurim Pharmaceuticals, Ltd.
Patents
Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus
US-11840731-B2
View DetailsMethod for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus
US-11807907-B2
View Details
Method for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus
US-11840731-B2
View DetailsMethod for diagnosing and treating subjects having single nucleotide polymorphisms in chromosome 2, 2:107,510,000-107,540,000 locus
US-11807907-B2
View DetailsProducts
Pediatric prolonged‑release melatonin mini‑tablet (1 mg / 5 mg)
Oral prolonged‑release melatonin mini‑tablet formulation indicated for pediatric insomnia associated with autism spectrum disorder, neurogenetic disorders and ADHD where sleep hygiene measures are insufficient.
Prolonged‑release melatonin tablet (2 mg) for older adults
Oral 2 mg prolonged‑release melatonin tablet indicated for short‑term treatment of primary insomnia characterized by poor sleep quality in patients aged 55 years and older.
Pediatric prolonged‑release melatonin mini‑tablet (1 mg / 5 mg)
Oral prolonged‑release melatonin mini‑tablet formulation indicated for pediatric insomnia associated with autism spectrum disorder, neurogenetic disorders and ADHD where sleep hygiene measures are insufficient.
Prolonged‑release melatonin tablet (2 mg) for older adults
Oral 2 mg prolonged‑release melatonin tablet indicated for short‑term treatment of primary insomnia characterized by poor sleep quality in patients aged 55 years and older.
Services
Collaborative development partnerships for early‑stage drug candidates in the CNS space.
Licensing agreements to enable regional promotion and distribution of marketed products and late‑stage pipeline assets.
In‑licensing partnerships to acquire rights to promote and distribute CNS therapies in specific territories.
End‑to‑end clinical development and regulatory activities including study execution and global registration support.
Collaborative development partnerships for early‑stage drug candidates in the CNS space.
Licensing agreements to enable regional promotion and distribution of marketed products and late‑stage pipeline assets.
In‑licensing partnerships to acquire rights to promote and distribute CNS therapies in specific territories.
End‑to‑end clinical development and regulatory activities including study execution and global registration support.
Expertise Areas
- Clinical trial management (Phase I–IV) for CNS indications
- Pediatric CNS therapeutics and pediatric formulation development
- Regulatory compliance and EMA/CHMP submissions
- Formulation development for prolonged‑release oral dosage forms
Key Technologies
- Prolonged‑release oral formulation
- Pediatric mini‑tablet oral dosage
- Clinical development methodologies (Phase I–IV)
- Regulatory submission processes (EMA/CHMP Marketing Authorization)
News & Updates
A successful gathering of international partners to promote better care for children with ASD.
Participation in IPSA 2024 Congress in Glasgow, focusing on insomnia in children with NDDs.
Launch of Slenyto in South Korea to improve lives of children with ASD.
Neurim received European marketing authorization for Slenyto® for insomnia in children with ADHD.
Neurim received a positive CHMP opinion for Slenyto® for treating insomnia in children with neurogenetic disorders.
Authorization for the treatment of insomnia in children with ADHD.
A successful gathering of international partners to promote better care for children with ASD.
Participation in IPSA 2024 Congress in Glasgow, focusing on insomnia in children with NDDs.
Launch of Slenyto in South Korea to improve lives of children with ASD.
Neurim received European marketing authorization for Slenyto® for insomnia in children with ADHD.
Neurim received a positive CHMP opinion for Slenyto® for treating insomnia in children with neurogenetic disorders.
Authorization for the treatment of insomnia in children with ADHD.